Angiogenic Factors in the Placentas of Women With COVID-19

NCT ID: NCT06644521

Last Updated: 2024-10-16

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 40 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2020-12-01
• Study Completion Date: 2023-04-17

Brief Summary

Aim: There have been few studies since the beginning of the pandemic researching the histopathologies and conducting molecular investigations of the placentas of SARS-CoV-2 positive pregnant women. The aim of this study was to analyze the changes in the expression of angiogenic growth factors in the placentas of pregnant women infected with SARS-CoV-2 (the COVID-19 group), and to make comparisons with the placentas of non-infected pregnant women (the control group).

Methods: Placentas taken at birth from 20 healthy women (control) and 20 women with a positive test for COVID-19 were prepared for histopathological examination. Immunohistochemical staining was applied in placental tissues with ACE2 (Angiotensin-conversion enzyme-2), VEGF (Vascular Endothelial Growth Factor), VEGFR-1 (Vascular Endothelial Growth Factor Receptor 1) and PDGF (Platelet-Derived Growth Factor).

Results: First, the presence of COVID-19 in the placental tissue was assessed by the ACE2 immunohistochemical method. It was seen that ACE2 was expressed weakly in the placental syncytiotrophoblast cells of non-infected women, but in the syncytiotrophoblasts of the placentas of women infected with COVID-19, ACE2 expression was much higher. VEGF in the endothelial and stromal cells of the villi of the control group was very strong, but in the villi of infected placentas it was significantly weaker. VEGFR-1 was positive in the endothelial membranes of the villi of the control group, but was significantly weaker in the villi of infected placentas. PDGF expression was strong in the syncytiotrophoblast and stromal cells of the control group, but was significantly noticeably weaker in COVID-19 positive placentas.

Conditions

COVID-19; Placenta Diseases; Angiogenesis

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Study Groups

Group 1: COVID-19 group

No interventions assigned to this group

Group 2: Control

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Covid-19 patients while pregnancy
• Age range 18-50
• Being literate in Turkish
• Not having any additional disease
• Agreeing to participate in the study

Exclusion Criteria

• High-risk pregnancies (gestational hypertension, preeclampsia, HELLP syndrome, chronic hypertension, gestational and pregestational diabetes, cholestasis, intrauterine growth retardation, etc.)
• Multiple pregnancy
• Pregnant women under the age of 18
• Smoking
• Medication use (excluding routinely used food supplements during pregnancy)
• Additional disease (thyroid, renal failure, liver failure, hepatitis, heart disease, connective tissue disease, etc.)
• Immunosuppressive use
• Presence of active or chronic infection
• Presence of active or chronic inflammatory disease
• Patients who gave birth at an external center or later chose to withdraw from the study
• Patients who did not have Covid-19 while pregnancy included in the control group

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: Yes

Sponsors

Celal Bayar University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Manisa Celal Bayar University

Manisa, , Turkey (Türkiye)

Countries

Turkey (Türkiye)

Other Identifiers

MCBU_Covidplasenta

Identifier Type: -

Identifier Source: org_study_id